Brief: Anika’S Cingal Successfully Achieves Primary Endpoint In Third Phase Study

Anika Therapeutics

01/11/2022 12:30

Nov 1 (Reuters) - Anika Therapeutics Inc  ANIK.O :
    * ANIKA’S CINGAL® SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT
IN THIRD
PHASE III STUDY
    * ANIKA THERAPEUTICS INC - PLANS TO MEET WITH FDA TO DISCUSS
NEXT
STEPS FOR U.S. REGULATORY APPROVAL
    * ANIKA THERAPEUTICS INC - ACTIVELY ASSESSING OPTIONS TO
ADVANCE
CINGAL, INCLUDING THROUGH POTENTIAL COMMERCIAL PARTNERSHIPS

Source text for Eikon:  ID:nGNX2jn1md 
Further company coverage:  ANIK.O 
 ((Reuters.Briefs@thomsonreuters.com;))